AI+ Taipei Startup Pitch Contest: Open Call for Applications From Now Until June 30th
TAIPEI CITY, May 27, 2025 /PRNewswire/ — Calling all Global Innovators! The Taipei Entrepreneurs Hub (TEH), under the Taipei City Department of Economic Development (DOED), is thrilled to announce the 'AI+ Taipei Startup Pitch Contest,' welcoming AI startups from across the globe to collaborate and redefine the future.
AI+ Taipei Startup Pitch Contest applications are open for submission and accepted until June 30, 2025, Taipei Time (UTC+8). Don't miss this chance to showcase your innovative ideas and be part of the forefront of AI innovation in Taipei.
To foster international talent exchange and industry collaboration, TEH is committed to advancing AI innovation, a key driver of economic growth and complex problem-solving. Through the 'AI+ Taipei Startup Pitch Contest,' we aim to attract top AI talent and startups, encouraging collaboration and unlocking new opportunities in Taipei.
This year, TEH has invited prestigious industry leaders and venture capital firms, including ASUS and SYSTEX, to serve as judges. International startups are encouraged to participate and develop market expansion plans targeting Taiwan. The 6 selected teams will be invited to Taipei for a Demo Day and business trip in late October, with travel and accommodation expenses fully covered by TEH, offering a unique opportunity to connect with potential partners and investors in Taiwan.
During their stay, customized matchmaking sessions and business itineraries will be arranged, facilitating networking and collaboration with Taipei-based companies, venture capital firms, and other key stakeholders.
The AI+ Taipei Startup Pitch Contest offers 6 global entrepreneurs a platform to exchange ideas, learn from leading AI experts, and forge partnerships with future collaborators and investors in Taiwan. Stay tuned for updates on the upcoming Demo Day, where top teams will showcase their innovative solutions in Taipei. Together, we look forward to building a brighter, AI-driven future.
About Taipei Entrepreneurs Hub (TEH):TEH, which was established in 2021, is a government-backed international community for innovative talents in Taipei. The goals include supporting foreign startups to soft-land in Taipei through online/offline programs like networking events, boot camps, pitch contests, match-makings, and Demo Day. For more information on our activities, please visit our official Facebook page at [Link] or our LinkedIn page at [Link].
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
an hour ago
- Malaysian Reserve
Telix's Illuccix® PSMA-PET Imaging Agent Approved in Portugal
MELBOURNE, Australia, June 4, 2025 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, 'Telix', 'the Company') today announces that its prostate cancer PET[1] imaging agent, Illuccix® (kit for the preparation of gallium-68 gozetotide injection), has been granted marketing authorization in Portugal by INFARMED[2] for the detection and localization of prostate-specific membrane antigen (PSMA)-positive lesions in adults with prostate cancer, a broad clinical label. This approval enhances the options available to healthcare providers across Portugal for PSMA-PET[3] imaging using a clinically validated gallium-based radiopharmaceutical. Illuccix, after radiolabelling with gallium-68, is indicated in Portugal for the detection of prostate-specific membrane antigen (PSMA)-positive lesions with PET in adults with prostate cancer (PCa) in the following clinical settings: Primary staging of patients with high-risk PCa prior to primary curative therapy. Suspected recurrent PCa in patients with increasing levels of serum prostate-specific antigen (PSA) after primary curative therapy. Identification of patients with PSMA-positive progressive metastatic castration-resistant prostate cancer (mCRPC) for whom PSMA-targeted therapy is indicated. PSMA-PET imaging represents a significant advancement in prostate cancer management, largely replacing conventional imaging methods such as bone scans and CT[4] scans as the standard of care after initial diagnosis and biochemical recurrence (BCR). Global guidelines recognise its superior accuracy in staging primary disease and assessing BCR[5]. Illuccix® PSMA-PET will help address an important clinical need by supporting timely and effective diagnosis, as well as identifying patients who may benefit from PSMA-targeted therapy. Illuccix's broad approval is supported by robust clinical data, including the largest Ga-68-based PSMA data set from the VISION trial[6]. Despite the proven benefits of PSMA-PET imaging, patients in Portugal have faced long wait times due to tracer shortages and infrastructure constraints. Dr. Fernando Abreu, Director of Nuclear Medicine at the Santa Maria Local Health Unit, commented, 'PSMA-PET imaging has significantly enhanced the accuracy and confidence in the detection and monitoring of prostate cancer. However, Portugal is currently facing a shortage of gallium-68 tracers, which has resulted in a national waiting list of up to six months. This delay has an impact on the timely diagnoses and treatments impacting patient care. The approval of Illuccix® in Portugal will be welcomed by physicians and patients as it allows hospitals and clinics to conduct PSMA-PET scans more efficiently, and with shorter wait times.' With its broad indication, Illuccix® is designed to support healthcare providers in delivering efficient and reliable imaging. The approval comes as demand for PSMA-PET continues to grow across Europe, reinforcing the need for solutions that fit within existing hospital workflows. Illuccix® will be distributed in Portugal by Sociedade Avanço, Unipessoal, LDA (Avanço), a specialist distributor of nuclear medicine, radiotherapy technologies and urology biopsy products. 'The approval of Illuccix® in Portugal marks an important milestone, providing healthcare professionals with access to a gallium-based PSMA-PET imaging agent supported by strong clinical validation. Our partnership with Avanço will help address the current shortages of gallium tracers and enable more efficient scanning processes. This collaboration reflects Telix's ongoing commitment to expanding access to high-quality prostate cancer imaging across Europe and reducing the barriers that currently delay diagnosis and treatment.' said Raphaël Ortiz, Chief Executive Officer, Telix International. Mr. Diogo Marcos, Managing Director of Avanço added: 'We are delighted to partner with Telix for the distribution of Illuccix® in Portugal. As the official distributor of the GalliaPharm®[7] generator, currently the only generator with marketing approval in the country, we are uniquely positioned to help address the national shortage of gallium-68. Our established distribution network ensures nationwide access, and our collaboration with Telix will enable us to support physicians in delivering timely and accurate PSMA-PET imaging.' Healthcare professionals in Portugal interested in ordering Illuccix® or learning more about availability can contact comercial@ or call (+351) 214 380 690. Prostate Cancer in Portugal Prostate cancer is the most common cancer in men in Portugal, with just over 7,500 new cases diagnosed annually, and a significantly higher incidence in men than either bowel (6,092 new cases) or lung cancer (4,253 new cases). Prostate cancer is also the third most common cause of cancer death in men, with just over 2,080 men dying from their disease in Portugal in 2022[8]. About Illuccix® Telix's prostate imaging product, gallium-68 (68Ga) gozetotide injection (also known as 68Ga PSMA-11 and marketed under the brand name Illuccix®), has been approved by the United States Food and Drug Administration (FDA)[9], by the Australian Therapeutic Goods Administration (TGA)[10], by Health Canada[11], by the Brazilian Health Regulatory Agency (ANVISA)[12], by the United Kingdom (UK) Medicines and Healthcare Products Regulatory Agency (MHRA)[13], by the French National Agency for the Safety of Medicine and Health Products (ANSM)[14] and in multiple countries within the European Economic Area (EEA)[15] following a positive decentralized procedure (DCP) opinion by the German medical regulator, BfArM[16]. About Telix Pharmaceuticals Limited Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, Brazil, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. ARTMS, IsoTherapeutics, Lightpoint, Optimal Tracers and RLS are Telix Group companies. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX). Visit for further information about Telix, including details of the latest share price, ASX and SEC filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook. Telix Investor Relations Ms. Kyahn Williamson Telix Pharmaceuticals Limited SVP Investor Relations and Corporate Communications Email: Legal Notices You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website. The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement. This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as 'may', 'expect', 'intend', 'plan', 'estimate', 'anticipate', 'believe', 'outlook', 'forecast' and 'guidance', or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix's good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix's business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix's business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix's preclinical and clinical trials, and Telix's research and development programs; Telix's ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix's product candidates, manufacturing activities and product marketing activities; Telix's sales, marketing and distribution and manufacturing capabilities and strategies; the commercialisation of Telix's product candidates, if or when they have been approved; Telix's ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix's expenses, future revenues and capital requirements; Telix's financial performance; developments relating to Telix's competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix's business; and the pricing and reimbursement of Telix's product candidates, if and after they have been approved. Telix's actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. ©2025 Telix Pharmaceuticals Limited. The Telix Pharmaceuticals®, Telix Group company, and Telix product names and logos are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved. Trademark registration status may vary from country to country. [1] Positron emission tomography. [2] National Authority of Medicines and Health Products, I.P. [3] Imaging of prostate-specific membrane antigen with positron emission tomography. [4] Computed tomography. [5] European Association of Urology (EAU) Guidelines. Edn. presented at the EAU Annual Congress Paris 2024. ISBN 978-94-92671-23-3.: Prostate cancer: European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2023: [6] ID: NCT03511664. VISION study sponsored by Endocyte, a Novartis company. Telix provided Illuccix (TLX591-CDx) for PSMA-PET imaging. [7] GalliaPharm® is a registered trademark of Eckert & Ziegler SE. [8] Global Cancer Statistics 2022: GLOBOCAN survey. Published August 2024. [9] Telix ASX disclosure 20 December 2021. [10] Telix ASX disclosure 2 November 2021. [11] Telix ASX disclosure 14 October 2022. [12] Telix ASX disclosure 18 March 2025. [13] Telix ASX disclosure 13 February 2025. [14] Telix media release 29 April 2025. [15] Czech Republic, Denmark, Finland, Ireland, Luxembourg, Malta, the Netherlands, Norway, Portugal and Sweden at time of release. [16] Telix ASX disclosure 17 January 2025. Logo – View original content:
Malaysian Reserve
an hour ago
- Malaysian Reserve
Kiwa PVEL Releases 11th Edition of the PV Module Reliability Scorecard
The total number of Top Performers remains steady, but failures have increased NAPA, Calif., June 4, 2025 /PRNewswire/ — Kiwa PVEL, the independent lab for quality and reliability testing of solar photovoltaic (PV) modules, today announced the publication of its 11th annual PV Module Reliability Scorecard. This digital resource provides solar industry stakeholders with testing insights gained from Kiwa PVEL's flagship Product Qualification Program (PQP). The PQP is a comprehensive suite of extended reliability and performance tests that evaluate solar modules under a wide range of environmental and mechanical conditions—including the effects of extreme temperatures and high humidity, as well as the impacts of mechanical stress, hail and ultraviolet light. In the 11th edition, Kiwa PVEL names a total of 50 manufacturers as 'Top Performers' in one or more of the tests, with nine manufacturers named as Top Performers with at least one model type listed in each of the seven test categories. Other Key Highlights from the 2025 Scorecard include: Only 21 model types achieved Top Performer status in all reliability tests (TC, DH, MSS, HSS, PID and LID+LETID), and of those, only three models were also Top Performers in PAN. There are mixed results across PQP tests, with some improving and others trending down. The PID and PAN results improved, but the module breakage rate for MSS and HSS has increased. Likewise, UVID results are starting to improve, but are still a source of concern for some. 83% of module manufacturers had at least one test failure, up from 66% reported in the 2024 Scorecard, which at the time was the highest percentage ever reported. 'The rapid pace of innovation in the PV module landscape is encouraging, and it's great to see more products achieving Top Performer status,' said Tristan Erion-Lorico, Vice President of Sales and Marketing at Kiwa PVEL. 'However, we continue to caution buyers not to assume all modules are created equal. Our testing continues to uncover significant variability in performance and long-term reliability. The Scorecard remains an essential tool for navigating these differences, helping procurement teams make smart, risk-conscious decisions.' The complete 2025 PV Module Reliability Scorecard is available online at Using the Top Performers tool allows users to explore detailed test results, filter by manufacturer, module type, and test category, and download custom search results for further analysis. 'Our 2025 Scorecard reveals both the progress and the challenges that come with a dynamic PV module market,' commented Kevin Gibson, Managing Director of Kiwa PVEL. 'For over a decade, we've rigorously tested modules to uncover reliability and performance trends, and this year was no exception. While not every test result exceeded our expectations, many did—demonstrating resilience and excellence in an evolving industry.' To be eligible for the 2025 Scorecard, manufacturers must have completed the PQP sample production factory witness after October 1, 2023, and submitted at least two factory-witnessed PV module samples to all PQP reliability tests, as per Kiwa PVEL's BOM test requirements. Visit the Scorecard online at About Kiwa PVELKiwa PVEL is the leading reliability and performance testing lab for downstream solar project developers, financiers, and asset owners around the world. As part of the larger Kiwa Group, Kiwa PVEL's integrated services for the solar supply chain offer technical solutions for mitigating risk, optimizing financing and improving solar and energy storage systems performance throughout the project lifecycle. For over a decade, Kiwa PVEL's Product Qualification Program (PQP) has been globally recognized for replacing assumptions about PV module performance with quantifiable metrics. Related data and consulting services offered by Kiwa PVEL provide vital procurement intelligence to a network of downstream solar buyers. Visit and to learn more. Logo – – View original content:
New Straits Times
an hour ago
- New Straits Times
US doubles steel, aluminum tariffs as OECD ministers gather
WASHINGTON: The United States doubled steel and aluminum tariffs Wednesday, casting a pall on a gathering of OECD ministers as President Donald Trump's intensifying trade war weighs on the world economy. Trump's sweeping tariffs on allies and adversaries alike – including levies on imported steel and autos – have strained US ties with trading partners and sparked a flurry of negotiations to avoid the duties. And pressure is mounting as the Organisation for Economic Cooperation and Development (OECD), a 38-nation grouping of mostly developed countries, cut its global growth forecast on the back of Trump's levies. Trade, consumption and investment have been affected by the tariffs, OECD chief economist Alvaro Pereira earlier told AFP, warning that the US economy will see the biggest repercussions. While some of Trump's most sweeping levies face legal challenges, they have been allowed to remain in place for now as an appeals process is ongoing. Against this tense backdrop, the Paris-based grouping is holding a ministerial meeting on Tuesday and Wednesday. US Trade Representative Jamieson Greer and EU trade commissioner Maros Sefcovic are set to hold talks on the sidelines of the gathering, with the bloc seeking to stave off higher levies from July 9 absent a compromise. Similarly, UK Trade Secretary Jonathan Reynolds met Greer on Tuesday to try and avert fresh tariff hikes on steel and aluminum. Despite the doubling of steel and aluminum tariffs Wednesday, imports from the UK will remain at 25 percent for now, while both sides work out duties and quotas in line with the terms of their trade pact. In their talks, Reynolds and Greer discussed a "shared desire to implement" the pact, including agreements on sectoral tariffs, as soon as possible, a UK readout said. But Trump's latest salvo raises temperatures with various partners. The European Union has said it "strongly regrets" Trump's plan to raise metals tariffs, cautioning that it "undermines ongoing efforts to reach a negotiated solution" with the United States. The bloc added that it was ready to retaliate. The Group of Seven advanced economies – Britain, Canada, France, Germany, Italy, Japan and the United States – is due to hold separate talks on trade on Wednesday too. "We need to come up with negotiated solutions as quickly as possible, because time is running out," German economy minister Katherina Reiche said Tuesday, on the sidelines of OECD talks. French trade minister Laurent Saint-Martin added: "We have to keep our cool and always show that the introduction of these tariffs is in no one's interest." Mexico will request an exemption from the higher tariff, Economy Minister Marcelo Ebrard said, arguing that it is unfair because the United States exports more steel to Mexico than it imports. "It makes no sense to put a tariff on a product in which you have a surplus," Ebrard said. Mexico is highly vulnerable to Trump's trade wars because 80 percent of its exports go to the United States, its main trading partner. On Tuesday, White House press secretary Karoline Leavitt confirmed the Trump administration sent letters to trading partners to push for offers by Wednesday as a deadline approached. Besides imposing 10 percent tariffs on almost all US trading partners in early April, Trump had announced higher rates for dozens of economies including the EU and Japan as he sought to pressure countries to correct practices Washington deemed unfair. These higher rates were paused for 90 days, but the halt is due to expire July 9. All eyes are also on rising tensions between Washington and Beijing. Trump has taken special aim at China this year, imposing additional levies of 145 percent on Chinese imports – triggering Beijing's counter tariffs of 125 percent on US goods. Both sides agreed to temporarily de-escalate in May, but Trump accused China of violating the deal. The issue was China "slow walking the approval" of critical mineral exports and rare earth magnets, US Deputy Treasury Secretary Michael Faulkender told CNBC on Monday. But he maintained Washington is making "good progress" overall in talks.
